WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data [Yahoo! Finance]
Wave Life Sciences Ltd. - Ordinary Shares (WVE)
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.wavelifesciences.com/news-releases?page=1%2c0%2c0%2c0
Company Research
Source: Yahoo! Finance
Shares of Wave Life Sciences WVE surged 74.1% on Wednesday after the company reported positive proof-of-mechanism data from an ongoing early to mid-stage study of its investigational candidate, WVE-006, for alpha-1 antitrypsin deficiency (AATD), a type of genetic disorder. WVE-006 is a GalNAc-conjugated oligonucleotide that enables A-to-I RNA editing and is administered subcutaneously. Developed with Wave Life Sciences' advanced oligonucleotide chemistry platform, it is specifically designed to target lung disease, liver disease, or both, related to AATD. Per the company, approximately 200,000 individuals in the United States and EU have AATD due to the SERPINA1 Z mutation. Current treatments are limited to weekly IV augmentation therapy, which targets lung disease and generated more than $1.4 billion in global sales in 2023. However, no approved therapies exist for AATD-related liver disease, often leading to liver transplants for affected individuals. WVE Achieves First-Ever
Show less
Read more
Impact Snapshot
Event Time:
WVE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WVE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WVE alerts
High impacting Wave Life Sciences Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
WVE
News
- Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024GlobeNewswire
- Wave Life Sciences Ltd. (NASDAQ: WVE) had its price target raised by analysts at B. Riley from $19.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Institutional investors in Wave Life Sciences Ltd. (NASDAQ:WVE) see US$94m decrease in market cap last week, although long-term gains have benefitted them. [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Ltd. (NASDAQ: WVE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.MarketBeat
WVE
Earnings
- 8/8/24 - Miss
WVE
Sec Filings
- 10/30/24 - Form 8-K
- 10/18/24 - Form 4
- 10/18/24 - Form 4
- WVE's page on the SEC website